You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Objective measures for the progression of Parkinson’s disease
  1. B Snow
  1. Auckland Hospital, New Zealand; 
 bsnow@adhb.govt.nz

    https://doi.org/10.1136/jnnp.74.3.287

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      Objective measure of the nigrostriatal dopaminergic deficit: evidence that SPECT does the job

      A persisting frustration in the diagnosis, treatment, and research of Parkinson’s disease is the lack of an objective measure of the nigrostriatal dopaminergic deficit. In particular, we need a tool to monitor the progress of the neuronal degeneration. This is very difficult to achieve clinically in Parkinson’s disease because of the complex clinical presentation and the confounding effect of symptomatic therapy. Although PET, with markers of presynaptic dopaminergic function such as 6-fluorodopa, is an …

      View Full Text

      Linked Articles